01/10/2007
ColostrininTM to be active ingredient in Metagenics’ CogniSureTM, a product being marketed as support for the maintenance of mental capacity.
ReGen Therapeutics Plc (London) announced today that its licensee Metagenics, Inc. has launched its cognitive nutraceutical, ColostrininTM, onto the US market. Metagenics Inc. is a leading supplier of natural medicines to healthcare professionals.
ColostrininTM is the active ingredient in Metagenics’ healthy cognition support formula, CogniSureTM. Initially CogniSureTM is being made available to consumers via Metagenics’ network of approximately 30,000 healthcare professionals across the USA. These include physicians, chiropractors, acupuncturists, nutritionists, and other healthcare professionals with a specific interest in nutritional supplementation. The product is being made available as chocolate flavour chewable tablets in blister packs containing 30 tablets. Further details of availability are provided on Metagenics’ website (www.metagenics.com). Commercial partners for subsequent retail channel distribution are currently being sought by ReGen and Metagenics.
The financial terms of this deal remain commercially confidential, although it can be confirmed that all agreements with Metagenics involve the sale and supply of the ColostrininTM active ingredient to Metagenics for them to formulate, package and market. ReGen then receives a royalty out of the sale proceeds when the formulated product is sold.
Percy Lomax, Executive Chairman of ReGen said, ‘After the successful launch of ColostrininTM in Australasia in July, the launch of ColostrininTM ‘as CogniSureTM‘ in the USA is a major milestone for ReGen. The USA is by far the largest natural medicines market in the world and we are therefore excited by the possibilities for sales.’
Dr. Jeffrey Bland, CSO and President of MetaProteomics(R) (a subsidiary of Metagenics), added, ‘We are very pleased to be introducing ColostrininTM to the USA. Based on feedback from customers in Australia and New Zealand and interest amongst practitioners here, we are optimistic that it will be well received in the USA and believe it will be an important breakthrough in helping to maintain the cognitive health of the ageing population here.’
Further information:
Percy Lomax
Chairman and Chief Executive
ReGen Therapeutics Plc
Tel: 020 7153 4920
Direct: 020 8504 2156
Mobile: 07932 751541
Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile: 07785 297111
Roland Cornish
Beaumont Cornish Limited
Tel: 020 7628 3396
Notes to Editors
About ReGen Therapeutics Plc
ReGen Therapeutics is a UK listed Biotech company which is developing three business lines-human and veterinary nutraceuticals, prescription pharmaceuticals for the treatment of neurodegenerative diseases and a clinical research organisation which oversees Phase I and Phase II both for ReGen and external customers. ReGen’s business strategy is to develop its nutraceutical and pharmaceutical products to a state where they can be licensed out and marketed by a third party. Its only direct sales are currently through its clinical research organisation: www.regentherapeutics.com
ReGen’s shares are traded on the AIM Market of the London Stock Exchange plc (RGT) and are quoted on the Pink Sheets of the United States over-the-counter market in the form of American Depositary Receipts (REGUY:PK).
About Metagenics, Inc.
Metagenics is a life sciences company and leading developer and manufacturer of science-based medical foods and nutraceuticals sold to healthcare practitioners worldwide. It is headquartered in San Clemente, CA, with manufacturing and research facilities located in Gig Harbor, WA, including the MetaProteomics(R) Nutrigenomics Research Center and the Functional Medicine Research CenterSM for human clinical research. Metagenics holds multiple proprietary formula patents and produces more than 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information, please visit www.metagenics.com.